This report was first published by Endpoints News. To see the original version, click here
Structure Therapeutics has its much-anticipated oral GLP-1 data, and the results look to give the next-generation contender a chance against market incumbents Eli Lilly and Novo Nordisk.
The biotech said Monday that its once-daily pill aleniglipron led to placebo-adjusted mean weight loss of 16.3%, or about 39 pounds, at the 180 mg dose at 44 weeks in Phase 2. On the 240 mg dose, the placebo-adjusted weight loss was 16%.
您已阅读14%（513字），剩余86%（3162字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。